KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Capital Expenditures (2016 - 2025)

Biogen (BIIB) has 17 years of Capital Expenditures data on record, last reported at $43.9 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 11.7% year-over-year to $43.9 million; the TTM value through Dec 2025 reached $153.8 million, changed 0.07%, while the annual FY2025 figure was $153.8 million, 0.07% changed from the prior year.
  • Capital Expenditures reached $43.9 million in Q4 2025 per BIIB's latest filing, down from $46.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $92.6 million in Q1 2021 and bottomed at $26.6 million in Q2 2025.
  • Average Capital Expenditures over 5 years is $54.1 million, with a median of $48.9 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 92.41% in 2023, then tumbled 52.83% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $51.6 million in 2021, then skyrocketed by 67.44% to $86.4 million in 2022, then decreased by 24.54% to $65.2 million in 2023, then crashed by 39.72% to $39.3 million in 2024, then increased by 11.7% to $43.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $43.9 million in Q4 2025, $46.2 million in Q3 2025, and $26.6 million in Q2 2025.